U.S. Residential REITs Stock News

When close to half the companies in the United States have price-to-earnings ratios (or "P/E's") above 20x, you may...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...

Key Insights Significantly high institutional ownership implies American Vanguard's stock price is sensitive to their...

Great Lakes Dredge & Dock Corporation ( NASDAQ:GLDD ), is not the largest company out there, but it received a lot of...

In January 2026, NWPX Infrastructure announced the first commercial use of its patent-pending Permalok Radial Bending Joint (RBJ) technology, supplying 5,764 linear feet of curved steel casing pipe for Tampa Bay Water’s South Hillsborough Pipeline microtunneling project, which includes 18 underground crossings. This curved RBJ system enables pipeline routes to bend around existing utilities and structures, potentially lowering construction disruption through fewer shafts, smaller sites, and...

If you are wondering whether Exelixis at US$45.44 is still a sensible entry or more of a hold, the key question is how its current price compares with its underlying value. The stock has logged returns of 2.9% over the past week, 9.2% over the past month, 4.3% year to date, 24.3% over one year, 174.9% over three years and 113.1% over five years. This naturally raises questions about risk, timing and what is already priced in. Recent attention around Exelixis has centered on its position in...

In early January 2026, Upstream Bio, Inc. presented at the 44th Annual J.P. Morgan Healthcare Conference, while analysts initiated and upgraded coverage around its asthma candidate verekitug and the upcoming Phase 2 VALINAT readout. The combination of growing physician enthusiasm for long-acting TSLP inhibition and expectations for the VALINAT data has sharpened investor focus on Upstream Bio’s clinical pipeline. Against this backdrop, we’ll examine how physician interest in verekitug and...

In recent weeks, Mineralys Therapeutics reported stronger-than-expected third-quarter 2025 results while advancing its lead drug lorundrostat toward a New Drug Application for uncontrolled hypertension and chronic kidney disease. At the same time, senior executives executed pre-arranged Rule 10b5-1 stock sales as lorundrostat gained recognition in JAMA’s Research of the Year Roundup and the company presented at the 15th Annual LifeSci Partners Corporate Access Event. Against this backdrop,...

On January 15, 2026, Galaxy Digital Inc. announced it had completed ERCOT’s Large Load Interconnection Study and secured approval for an additional 830 megawatts of computing demand at its Helios data center campus in West Texas, lifting total approved and contracted power capacity at the site to over 1.6 gigawatts. This substantial power upgrade underpins Galaxy’s ambition to build a multi-tenant, multi-campus, multi-gigawatt platform for AI and high-performance computing workloads, using...

If you are wondering whether First Solar's share price still makes sense after recent moves, you are not alone. This article is designed to help you judge the current value with a clear framework. At a last close of US$243.64, the stock has had a 1.1% decline over the past week, a 5.8% decline over the past month, an 11.2% decline year to date, yet a 27.6% return over 1 year, 47.7% over 3 years and 126.6% over 5 years. This naturally raises questions about how much of the story is already in...

Antero Midstream (AM) has kept its quarterly cash dividend at $0.225 per share, alongside fourth quarter share repurchases and new senior notes offerings that reshape how cash flows between the company and its investors. See our latest analysis for Antero Midstream. At a share price of US$17.84, Antero Midstream has seen a 7 day share price return of 2.94% while its 1 year total shareholder return of 15.25% and 5 year total shareholder return above 200% reflect gradually building momentum...

If you are wondering whether Rezolve AI's recent run makes the stock look cheap or stretched, this article walks through what the current price could imply about its value. The shares last closed at US$4.62, with returns of 24.5% over 7 days, 55.6% over 30 days, 61.0% year to date and 53.5% over 1 year, while the 3 year return sits at a 54.2% decline. Recent price moves have come as Rezolve AI continues to attract attention in the AI and software space, where investor interest can quickly...

STAAR Surgical recently reshaped its board after shareholders rejected a proposed merger with Alcon, adding three investor-affiliated directors while CEO Stephen Farrell stepped down from the board but remains in the role until January 31, 2026. This shift hands greater influence to major shareholder Broadwood Partners and its allies, signaling potential changes in governance priorities and capital allocation for the standalone company. With Broadwood-backed directors now on the board, we’ll...

H.B. Fuller FY 2025 earnings snapshot H.B. Fuller (FUL) has wrapped up FY 2025 with fourth quarter revenue of US$894.8 million and basic EPS of US$0.55, setting the tone for a year where earnings momentum and margin progression were in focus for investors. The company has seen quarterly revenue move from US$917.9 million in Q3 2024 to the US$788.7 million to US$898.1 million range across the first three quarters of 2025, while basic EPS shifted from US$1.01 in Q3 2024 to US$0.24, US$0.77 and...

If you have been wondering whether Omnicom Group's share price still reflects its underlying business, this article walks through what the current numbers actually say about value. The stock last closed at US$80.84, with returns of 2.6% over the past 7 days, 0.2% over the past 30 days, a 0.6% decline year to date and a 2.3% decline over the past year. This is set against gains of 8.8% over 3 years and 52.6% over 5 years. Recent coverage has focused on how global advertising and marketing...

Why AIRO Group Holdings (AIRO) Is Back on Investors’ Radar Recent coverage around AIRO Group Holdings (AIRO) has zeroed in on its liquidity position and upcoming execution milestones, which together help explain the renewed interest you might be seeing in the stock. See our latest analysis for AIRO Group Holdings. After a sharp 71.65% 30 day share price return and a 42.86% year to date share price return, AIRO’s recent pullback, including a 24.57% 90 day share price decline and softer 1 day...

If you are wondering whether Mercury Systems' recent share price strength still leaves any value on the table, this breakdown is designed to help you weigh the upside against the risks. The stock last closed at US$102.95, with returns of 16.0% over 7 days, 43.4% over 30 days, 35.4% year to date, 140.2% over 1 year and 119.4% over 3 years, which naturally raises questions about how the current price lines up with underlying value. These moves have played out alongside ongoing investor...

Recent trading in Coursera (COUR) has drawn attention after a series of negative returns, including about a 19% decline over the past month and roughly 35% over the past 3 months. See our latest analysis for Coursera. Those short term share price declines sit within a tougher stretch for investors, with the year to date share price return at about an 8% decline and the 1 year total shareholder return around a 25% loss. This hints at fading momentum as the market reassesses Coursera’s growth...

If you are wondering whether Ubiquiti’s recent share price puts it at an attractive entry point or a stretched one, this article walks through the key valuation angles you should be thinking about. The stock last closed at US$553.52, with returns of 0.8% over 7 days, a 0.9% decline over 30 days, a 2.3% decline year to date, and a 35.6% gain over 1 year, alongside gains of 104.0% over 3 years and 122.0% over 5 years. Recent price moves are best viewed against ongoing investor interest in...

If you are wondering whether DENTSPLY SIRONA’s share price reflects its underlying worth, you are not alone. This article walks through what the current market price might be implying about value. The stock closed at US$12.58, with returns of 0.8% over the past week and 10.6% over the past month, set against a year to date return of 11.6% and a 1 year return of a 28.4% decline. Recent coverage has focused on how investors are reassessing dental and medical equipment names like DENTSPLY...

ORIC Pharmaceuticals (ORIC) stock has been in focus after fresh buy ratings from several research firms coincided with encouraging trial updates for its lead oncology drugs and a new collaboration with Johnson & Johnson. See our latest analysis for ORIC Pharmaceuticals. The recent news flow and analyst enthusiasm appear to be feeding into the share price, with ORIC’s 7 day share price return of 36.33% and year to date share price return of 41.00% standing against a 1 year total shareholder...

Wells Fargo downgrade puts Knife River in focus Wells Fargo’s decision to downgrade Knife River (KNF) to Equal-Weight while lifting its price target to $81 has put fresh attention on the stock and how analysts currently view its prospects. See our latest analysis for Knife River. Knife River’s recent momentum has been firm, with a 23.6% 90 day share price return and year to date share price return of 10.31% taking the stock to $80.24, even though the 1 year total shareholder return is a...

In its recent quarterly update, Global Industrial reported year-on-year revenue growth of 3.3% but missed analyst expectations on sales, EBITDA, and EPS, marking the slowest revenue growth and weakest performance versus estimates among maintenance and repair distributors. The results also underscored ongoing supply chain and inventory management difficulties, emphasizing how operational execution remains a central issue for the company and its peers. Next, we will examine how Global...

Insteel Industries (IIIN) opened its new fiscal year with Q1 2026 revenue of US$159.9 million and basic EPS of US$0.39, alongside net income of US$7.6 million. The company has seen revenue move from US$129.7 million and EPS of US$0.06 in Q1 2025 to a trailing twelve month revenue base of US$677.9 million and EPS of US$2.44. This gives investors a clearer sense of the earnings power behind the latest quarter and the improvement in net margin from 3.6% to 7% over the past year. See our full...